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Regulatory authoritya b s t r a c t
This article reviews the off-label recommendations and use of vaccines, and focuses on the differences
between the labelled instructions on how to use the vaccine as approved by the regulatory authorities
(or ‘‘label”1), and the recommendations for use issued by public health advisory bodies at national and
international levels. Differences between public health recommendations and the product label regarding
the vaccine use can lead to confusion at the level of vaccinators and vaccinees and possibly result in lower
compliance with national vaccination schedules. In particular, in many countries, the label may contain reg-
ulatory restrictions and warnings against vaccination of specific population groups (e.g. pregnant women)
due to a lack of evidence of safety from controlled trials at the time of initial licensure of the vaccine, while
public health authorities may recommend the same vaccine for that group, based on additional post-
marketing data and benefit risk analyses.
We provide an overview of the different responsibilities between regulatory authorities and public
health advisory bodies, and the rationale for off-label use2 of vaccines, the challenges involved based on
the impact of off-label use in real-life. We propose to reduce off-label use of vaccines by requiring the man-
ufacturer to regularly adapt the label as much as possible to the public health needs as supported by new
evidence. This would require manufacturers to collect and report post-marketing data, communicate them
to all stakeholders and regulators to extrapolate existing evidence (when acceptable) to other groups or to
other brands of a vaccine (class effect3). Regulatory authorities have a key role to play by requesting addi-
tional post-marketing data, e.g. in specific target groups. When public health recommendations for vaccine
use that are outside labelled indications are considered necessary, good communication between regulatory
bodies, public health authorities, companies and health care providers or vaccinators is crucial.
Recommendations as well as labels and label changes should be evidence-based. The rationale for the discrep-
ancy and the recommended off-label use of a vaccine should be communicated to providers.
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The introduction of vaccines into the market, as for any medic-
inal product, is a multi-step process and the result of a complex
interaction between several players. The first step is the granting
of the market authorization4 of the vaccine by the National Regula-
tory Authority (NRA), i.e. authorizing the use of the vaccine for a
given indication after assessment of the evidence supporting quality,
safety and efficacy in the population where it will be used. The next
step involves a public health advisory body which will issue public
health recommendations for the use of the vaccine.5
However, the public health recommendations may differ from
the indications contained in the label [1]. Discrepancies will result
in settings where the vaccine has been granted a marketing autho-
rization for a certain indication in a certain population with a
specific schedule, while it is recommended for use by the public
health bodies for a different or extended indication and/or in a dif-
ferent target group within a population and/or with a different
schedule. This would lead to a so called ‘‘off-label” public health
use. This occurs for instance when a vaccine label contains restric-
tions and warnings against vaccination of specific population
groups such as pregnant women, based on a lack of evidence of
safety in this group, while public health authorities may recom-
mend that the same vaccine should be used in this group, based
on benefit risk analyses and post-marketing data. Another example
of differences in schedule is the recommendation of the Canadian
public health authorities in 2006 to use the heptavalent pneumo-
coccal conjugate vaccine (PCV7) in infants in a 3 dose schedule
(2 + 1) although the vaccine was licensed for 4 doses (3 + 1) in
Canada [2]. Yet another example is that of the recommended use
of fractioned doses of inactivated poliomyelitis vaccine recom-
mended by Strategic Advisory Group of Experts on immunization
(SAGE) in the context of the current challenges in the supply of
vaccine [3]. These discrepancies may create confusion for vaccina-
tors as well as for vaccinees and could contribute to vaccine hesi-
tancy and reduced vaccination coverage. There is thus a need to
understand and, where possible, develop strategies to reduce dis-
crepancies between the labelled indication of a vaccine and public
health recommendations for its use that fall outside the label.nting of the market organization: Positive outcome from the registration
: the regulatory authority has decided that the benefit/risk balance is positive
ven indication (not necessarily the requested indication). In many countries a
m is: giving a license, registration or approval.
several industrialized countries there is also a price setting and decision on
rsement step.This article focuses on the off-label use of vaccines in public
health recommendations. Based on assessment of regulatory docu-
ments, literature review and consultation with key stakeholders,
we review the processes and responsibilities involved in marketing
authorization and public health recommendations for a vaccine
use, describe the rationale and circumstances for public health rec-
ommendations beyond the vaccine label, present the challenges
involved and propose a number of approaches to address these
complex situations.2. Market authorization and vaccine label
2.1. The registration process
Before a market authorization is granted by a NRA, a vaccine has
to go through a registration process6 that includes an assessment of
the vaccine quality, safety and efficacy for the requested indication
in the population where it will be used. The long process of registra-
tion begins with the assessment of the quality data (on the produc-
tion process) as well as non-clinical data (from in vitro and animal
models) to support the first-in-human studies [4,5]. Thereafter, the
data generated during the clinical trials in the phases 1, 2 and 3
are assessed and a risk-management plan is developed that
describes the planned post-marketing studies that should take place
after vaccine introduction [6]. The decision to grant a market autho-
rization for the vaccine is driven by the concept of ‘‘Benefit Risk Bal-
ance”. This process of assessing the Benefit Risk Balance involves the
evaluation of all available data on the desirable (benefits) and unde-
sirable effects (risks) of the vaccine, taking into account as well the
scientific evidence (data from clinical trials) and the uncertainties
(e.g. real world use of the vaccine, missing data, rare events, etc.).
The beneficial effects are then weighted against the potential unde-
sirable effects, taking into account the uncertainties, possible out-
comes and their respective importance [7].
In proposing a vaccine label, manufacturing companies7 should
comply with regulatory standard requirements (policies) and
include all required information in the vaccine label. In the European
Union, this is called the Summary of Product Characteristics (SmPC)6 Registration process: All activity performed by the regulatory authority to come
to a benefit risk balance to grant or not a marketing authorisation. The process is
characterized by assessment of all the available evidence on the quality, non-clinical
and clinical safety and efficacy aspects of the product.
7 In order to simplify the text, only one word is used to indicate the owner of the
medicinal product, the legal entity responsible for the product, see Glossary for more
details.
Table 1
Label definitions in the Summary of Product Characteristics (SmPC) according to EU guidance [9].
4.1 Therapeutic indications The indication(s) should be stated clearly and concisely and should define the target disease or condition distinguishing between
treatment (symptomatic, curative or modifying the evolution or progression of the disease), prevention (primary or secondary) and
diagnostic indication. When appropriate it should define the target population especially when restrictions to the patient
populations apply.
4.2 Posology and method of
administration
In case of restricted medical prescription, this section should be started by specifying the conditions.
In case of specific safety need, any recommended restriction to a particular setting should also be stated (e.g. ‘‘restricted to hospital
use only” or ‘‘appropriate resuscitation equipment should be available”).
4.3 Contraindications Situations where the medicinal product must not be given for safety reasons, i.e. contraindications, are the subject of this section.
Such circumstances could include a particular clinical diagnosis, concomitant diseases, demographic factors (e.g. gender, age) or
predispositions (e.g. metabolic or immunological factors, a particular genotype and prior adverse reactions to the medicine or class
of medicines). The situations should be unambiguously, comprehensively and clearly outlined.
4.6 Fertility, pregnancy and
lactation
Pregnancy
In general, clinical and non-clinical data should be followed by recommendations.
With respect to non-clinical data,
 Only conclusions of the reproductive toxicity studies should be included in this section. Further details should be provided in
Section 5.3.With respect to clinical data,
 The section should include comprehensive information on relevant adverse events reported in the embryo, the foetus, neonates
and pregnant women, when appropriate. The frequency of such events (for example the frequency of birth defects) should be
specified when available.
 The section should specify the extent of the human experience if no adverse events have been reported in pregnancy.
Table 2
Label for use in Pregnant women as documented in the EMA summary of product characteristics (SmPC) [9].
‘‘. . .There are no or limited amount of data from the use of [Vaccine] in pregnant women,
A: Studies in animals have shown reproductive toxicity (see Section 5.3).
[or]
B: Animal studies are insufficient with respect to reproductive toxicity (see Section 5.3).
[Vaccine] is not recommended during pregnancy and in women of childbearing potential not using contraception
P. Neels et al. / Vaccine 35 (2017) 2329–2337 2331[8,9], that contains structured information for both the prescriber
and the vaccinee. The information for use of the vaccine is supported
by the evidence generated by clinical trials [8,9]. In some instances,
regulators may not authorize the vaccine use for an indication that is
requested by the company,8 if they consider that the evidence is not
convincing.
After an initial label is approved, additional post-marketing
data may support or require a change in the label. The company
may perform additional clinical studies (observational or clinical
trials) to support an extension of the label to specific population
groups, other age groups or support different schedules or routes
of administration.9 These additional data may also be requested
by the NRAs. Additional data considered by the NRA can include data
generated by the company or by academia or public health
institutes.
2.2. Specific population groups
Current practice for many regulators is that the initial label
indications for a vaccine will be limited to the populations tested
in the clinical trials where evidence supports safety and efficacy
of vaccine use or where convincing bridging data exist. Label
advice for other high-risk and special populations may contain
cautionary statements when there is insufficient evidence to sup-
port the use in these groups. This lack of evidence means that it
is unknown if the vaccine is safe or effective in these groups.
A downside of this approach is that clinical trials usually involve
healthy and immune-competent populations, to optimize the
probability to demonstrate efficacy and avoid harm to vulnerable
populations. They tend to exclude participants with underlying8 Company: Marketing authorisation holder (license holder): the legal entity that
was granted the permission to market/sell the medicinal product. Manufacturer: the
legal entity that is producing the medicinal product. Not necessarily the same legal
entity that has the marketing authorisation.
9 Every change of the label has to be submitted to the NRA for approval, this is
called a variation procedure.diseases, such as cardiovascular disorders, renal failure, diabetes,
neuro-degenerative or psychiatric disorders and immune deficien-
cies. Some groups may also be excluded for ethical, liability or
safety concerns.
There is a clear paradox. Patients with underlying disease are
generally at higher risk of serious infections from vaccine-
preventable diseases and could thus benefit most from vaccination.
However, their exclusion from clinical trials results in a lack of
robust evidence either for the efficacy or the safety of the vaccine
in these groups. Where high-risk groups have been excluded from
clinical trials, it is often not justified to extrapolate safety and effi-
cacy to these groups without further evidence.
An important example of a group often excluded from the ini-
tially approved label is that of pregnant women. Pregnant women
(and their foetus) are routinely excluded from clinical trials and a
general warning in the label is included in the section on Preg-
nancy due to lack of data (Tables 1 and 2) [10]. Requests for label
changes related to use in pregnant women would likely not be sup-
ported by robust clinical trial evidence, but rather by surveillance
reports of sporadic and/or inadvertent use of the vaccine in preg-
nant women. These data are rarely published in peer reviewed
journals and their evaluation is hampered by limited details on
the vaccine used, medium or longer term outcomes, and lack of
access to the medical records of mother and infant. Regulatory
authorities are reluctant to accept these lower levels of evidence
for the purpose of label change. The United States (US) Food and
Drug Administration (FDA) issued new standards for pregnancy
and lactation product label in June 2015 that are intended to sim-
plify the use of vaccines and other medicinal products for this
group [11,12]. Under the new Pregnancy and Lactation Labelling
Rule, labels will be required to include three detailed subsections
Pregnancy, Lactation, and Females and Males of Reproductive Poten-
tial. Each section will include a risk summary, a discussion of the
supporting data, and relevant information to help providers make
prescribing and counselling decisions [13,14]. If no data are avail-
able to guide decision making, this must be stated [15].
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Another problem is that, even when evidence is sufficient to
approve the use of a particular vaccine from one company, NRAs
will be reluctant to accept the extrapolation and application of this
evidence to a similar vaccine from another company, due to the
uncertainty that the two vaccines will have the same quality, clin-
ical safety and efficacy. However, exceptions have occurred when
sufficiently justified. For instance in the EU, a ‘‘class effect” has
sometimes been accepted by regulators to change the label for
all brands of a certain vaccine. A class effect is ‘‘an effect of a group
of drugs with similar chemical structure and/or drugs with similar
mechanism of action and/or drugs with similar pharmacological
effects” [15,16]. The US FDA also developed the concept of ‘‘class-
wide label changes” which assumes that all products within a class
are closely related in chemical structure, pharmacology, therapeu-
tic activity, and adverse reactions [17,18].
There are a number of examples of class effects accepted by reg-
ulators, usually for safety reasons. In vaccinology, intussusception
is considered by regulatory authorities as a class effect of live rota-
virus vaccines [19]. For the trivalent inactivated influenza vaccines
(TIV), the EU regulators have now accepted a generic wording for
pregnancy based on class label [20,21], advocating that TIV use
during pregnancy in all trimesters is acceptable. EU regulators also
accept to some extent the concept of interchangeability in case of
co-administered vaccines: PCV7 (Prevenar) has shown efficacy in
co-administration with one brand of Diphtheria-Tetanus-Pertussis
(DTP) -containing vaccine, and all vaccines of the DTP class have
been approved for co-administration. Thus the class effect may
be accepted by regulators on a case-by-case basis.
2.4. Variations between countries
Vaccine labels may also differ between countries as a conse-
quence of the variation among independent regulatory authority
assessments, policies and other criteria used in the vaccine assess-
ment. First, the same evidence could lead to a label indicating use
in specific groups in one country, while another country’s regula-
tory body may have a different interpretation of the evidence
and science and decide that the evidence is not sufficient to
approve that same vaccine for the labelled use in the same groups
in their country. Second, the assessment of the benefit risk balance
by the NRA will be based on national methods, standards and laws.
Divergent regulatory decisions are illustrated by the following
examples. The live-attenuated seasonal influenza vaccine Flu-
mist,10 is indicated in adults aged up to 49 years in the US while
EU regulators have granted Fluenz the marketing authorisation
for children only (up to 18 years) based on the same evidence
[22,23]. In 2013, the EMA approved the change from a three-dose
Human Papillomavirus (HPV) vaccine schedule to a two-dose sched-
ule for children between 9 and 14 years [24,25], whereas HPV vacci-
nes in the US were still approved in a three-dose schedule in this age
group [26,27].3. Public health recommendations for vaccine use
In an increasing number of countries, national policies are for-
mulated by a National Immunization Technical Advisory Group
(NITAG), composed of independent experts in the field of immu-
nization and serving as technical resource providing guidance to
national policy-makers and programme managers to enable them
to make evidence-based immunization-related policy and pro-
gramme decisions. This sometimes causes off-label recommenda-10 In the EU this vaccine is named Fluenz.tions as the package insert text is not available to the NITAG
until after the license is granted.
In 2015, 64% of World Health Organization (WHO) Member
States had their own NITAGs, which provide recommendations to
decision makers, vaccinators and the general public on the imple-
mentation and use of vaccines at the (sub)national level [1,28].
Independent scientific assessments by NITAGs will inform the pub-
lic health recommendations for a particular vaccine. However,
NITAG assessments may reach different conclusions from those
of regulatory authorities, and NITAG’s recommendations may lie
outside the approved labelled use [1,8]. Discrepancies may then
arise when a vaccine has been granted marketing authorisation
by the regulatory authorities for a particular indication in a certain
population with a specific schedule, whereas the NITAG may rec-
ommend its use with a different indication, schedule, and/or pop-
ulation group.
Global public health recommendations are developed on an
international level by WHO. SAGE is a WHO committee formulat-
ing recommendations on vaccine use at the global level [29]. A
WHO SAGE recommendation is intended to help provide guidance
to national recommendations formulated by NITAGs. For example,
SAGE recommended to include pregnant women among the prior-
ity target groups for influenza vaccines [30,31], although the label
of these vaccines at the time did not recommend use during preg-
nancy in most countries. This SAGE recommendation contributed
to the inclusion of pregnant women in the influenza vaccination
target groups in a substantial number of countries, including 27
EU countries by 2015 [32].
There are four main reasons why recommendations for vaccine
use issued by NITAGs and SAGE may differ from the labelled indi-
cations initially issued by regulators. First, NITAGs and regulators
do not use exactly the same information to inform their decisions.
NRAs mostly consider the information that is submitted by the
company in the applications, as well as published and unpublished
data. NITAGs may not have access to all the scientific information
available during the registration process, as part of it is not publicly
available and they also consider additional information from other
sources such as trials published after vaccine authorisation and
post-marketing data on vaccine effectiveness, as well as impact
and safety generated after large-scale use of the vaccine. This addi-
tional information will be considered by the NRA for updates of the
label. For instance, the public health recommendation to use PCV7
(Prevenar) in a 2 + 1 schedule (instead of the licensed 3 + 1 at that
time) in Canada, Belgium and the United Kingdom was based on
evidence from immunogenicity trials and a large US effectiveness
study published after PCV7 authorisation [2,33]. Second, NITAGs’
decisions regarding vaccine use are not based exclusively on the
scientific evidence of efficacy and safety; they also take into con-
sideration a wide range of parameters including the age-specific
pre-vaccine disease burden, public health needs, other health
interventions, costs and cost-effectiveness, programmatic issues
such as existing schedules, acceptability, impact on equity and
policies that are specific to the country or region [1,34,35]. Like-
wise, SAGE recommendations consider data relevant for different
epidemiological settings, as some data (including local epidemiol-
ogy) from one region may not be appropriate for extrapolation to
another region. Thus, public health recommendations may differ
across countries and WHO regions. Third, both NITAGs and SAGE
have a different perspective than regulators. Their focus is on opti-
mizing the impact of vaccines and health benefits in the population
keeping in mind the potential role of other health intervention and
opportunity costs. Fourth, NITAGs will usually not make a product-
specific recommendation unless only a single product is granted a
marketing authorisation in a country (e.g. NITAGs usually do not
specify which of the available hepatitis A vaccines should be used).
One or more of these reasons may lead to public health recommen-
Table 3
Definitions of off-label use.
EMA [57] Off-label use relates to situations where a medicine is intentionally used for a medical purpose not in accordance
with the authorised product information.
Off-label use includes use in non-authorised paediatric age categories. Unless specifically requested, it does not
include use outside the EU in an indication authorised in that territory which is not authorised in the EU.
FDA [58–60] Off-label use is defined (called unlabelled indication) under the perspective of the health care provider only, i.e.
when a marketed drug is prescribed to treat a patient for an unlabelled indication
American academy of pediatrics committee on
drugs [42]
Off-label use of an approved drug refers to a use that is not included in the approved label
MEDRA [61] Off-label use is defined as a practice of prescribing pharmaceuticals outside the scope of the drug’s approved label,
most often concerning the drug’s indication.
Health Canada [62] Health Canada approves drugs for specific indications included in the drug’s official product monograph which is
part of the Notice of Compliance (NOC). Many off-label drug uses are effective, well documented in the peer-
reviewed literature, and widely used. Off-label or unlabelled drug use occurs when a drug is used in a treatment
regime or patient population that is not included in the NOC, and a drug is used for an indication other than those
specifically included in the NOC.
L’Ecluse et al. [63] The term off-label use refers to the prescribing or administration of an authorised medicinal product outside any of
the terms of the marketing authorisation, as reflected in the Summary of Product Characteristics (SmPC). This might
include use for a different indication, at a different dosage (or dosage frequency) or in a different patient group (for
example, children or pregnant women).
Prof. Y. Hekster MEB (Medicines Evaluation
Board, the Dutch NRA) [64]
Off-label use is the practice of prescribing drugs outside the scope of the drug’s indication and dosing, and especially
for other patient groups such as children.
Off-label use is no use of a registered medicine: no registration, no label and is not experimental use of a medicinal
product, either in a clinical trial or outside of a clinical setting (approved by an Ethics Committee).
Table 4
Examples of off-label use of vaccines.





At licensure, Prevenar (PnC7 conjugated 7-valent
pneumococcal vaccine) was approved in a 3 + 1 schedule:
infants should receive a primary vaccination of 3 injections
with a booster in the second year of life.
In Canada the National Advisory Committee on
Immunization (NACI) [2] decided to recommend an off-label
schedule: 2 + 1 instead of the approved 3 + 1.
In 2004 the EU regulators accepted the 2 + 1 schedule, which





Fertility The recommendation of this vaccine in this group, which is
official in the UK– is off-label considering the approved
SmPC.
No fertility data are available.
Pregnancy
The effect of REPEVAX on embryo-foetal development has
not been assessed. No teratogenic effect of vaccines
containing diphtheria or tetanus toxoids, or inactivated
poliovirus has been observed following use in pregnant
women. Limited post-marketing information is available on
the safety of administering REPEVAX to pregnant women.







US FDA: GARDASIL should be administered intramuscularly
as a 0.5-mL dose at the following schedule: 0, 2 months,
6 months [27].
The WHO SAGE recommended the 2-dose schedule for
adolescents in 2014 [68], which would be off-label use of
Gardasil in the US and in some other regions of the world (as
of March 2015).
EMA: Individuals 9 to and including 13 years of age EMA has approved recently the 2 dose schedule for
adolescents for both HPV vaccines.Gardasil can be administered according to a 2-dose schedule
(0.5 ml at 0, 6 months) (see Section 5.1).
If the second vaccine dose is administered earlier than





DUKORAL is indicated for active immunization against
disease caused by Vibrio cholera serogroup O1 in adults and
children from 2 years of age who will be visiting endemic/
epidemic areas. The use of DUKORAL should be determined
on the basis of official recommendations taking into
consideration the variability of epidemiology and the risk of
contracting disease in different geographical areas and
travelling conditions. DUKORAL should not replace standard
protective measures. In the event of diarrhoea measures of
rehydration should be instituted [69].
The company claims not only efficacy against cholera but also
against E. Coli. However this indication was not accepted by
the EU authorities [70]. A recommendation to vaccinate with





Active immunization against invasive disease, pneumonia
and acute otitis media caused by Streptococcus pneumoniae
in infants and children from 6 weeks up to 5 years of age. See
Sections 4.4 and 5.1 for information on protection against
specific pneumococcal serotypes [71].





Prophylaxis of influenza in individuals 24 months to less than
18 years of age [23].
Recommendation before or after this age category is off-label
use in the EU.
a In reference [67] on page 13 a description is given on the type II variation that led to a change of the SmPC to add the 2 + 1 schedule in the posology.
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indication, population group or schedule that differs from the indi-
cations granted in the marketing authorization [1].
4. Off-label public health use of vaccines
Off-label use of medicines or vaccines has no standard defini-
tion, and a number of published definitions are provided in Table 3.
Most of them define off-label use as a prescription for a different
indication, posology, age or, population group from that included
on the label. This review addresses the public health recommenda-
tion for off-label use of a vaccine, in which the vaccine is explicitly
recommended outside the approved label, as illustrated by exam-
ples in Table 4.11
There are differences in how off-label use is perceived through-
out the world [36]. In the EU, off-label use by health care providers
is a reason for concern and has received increasing attention as
illustrated by a 2013 resolution of the European Commission (EC)
calling for specific action regarding the off-label use of medicines
[37]. In particular, an EC study has been conducted to further
investigate off-label use in the EU. The European Federation of
Pharmaceutical Industry and Associations (EFPIA) has stated that
the off-label use should not be promoted by NITAGs or other offi-
cial bodies [38]. However, off-label use of certain medicines is
commonly accepted in some countries, such as the United King-
dom and France [39,40]. In countries such as in North America,
off-label use is more accepted as prescribers are responsible for
their prescriptions, including off-label use of a particular drug
[41]. For vaccines, public health recommendations set the standard
of care and even if off-label, these recommendations should be and
most often are followed by those delivering vaccines.
5. Challenges encountered in off-label use
Without proper explanation and communication from public
health authorities to health care providers, vaccinators and vacci-
nees may not understand the reasons for discrepancies between
the label and the recommendations. This could diminish confi-
dence in public health recommendations and contribute to vaccine
hesitancy, decreased adherence to national immunization sched-
ules and/or public health recommended vaccine use if it is outside
the labelled use [42]. Decreased vaccine coverage rate in a given
region may ensue. For instance, the US Advisory Committee on
Immunization Practices (ACIP) recommended in 2011 routine vac-
cination of pregnant women against pertussis to confer short-term,
early protection against pertussis for their infants through mater-
nal immunization [43]. The US label for combined tetanus, diph-
theria, pertussis (dTap)12 vaccines does not include that use; for
instance the US label for the dTap vaccine Boostrix states: ‘‘Safety
and effectiveness of BOOSTRIX have not been established in
pregnant women” [18]. Low uptake was observed as in 2012, only
16–20% of women with live births at the Vaccine Safety Datalink
sites received dTap during pregnancy [44].
Safety is another issue. Vaccines are designed and tested to
ensure safety in the vaccinated population. However the use of
some vaccines outside the label may be unsafe in certain instances.
For instance, age labelling can be related to proven safety issues,
e.g. the use of yellow fever vaccines in infants below six months
of age is an absolute contraindication in the EU due to a risk of11 In addition to this public health off-label use, an individual clinician may also
decide to use a vaccine outside the labelling advice. This may occur when, after
considering the benefits and the risks for a specific patient, the clinician considers
that the patient would likely benefit from the vaccination. This type of off-label use is
not considered in this review.
12 dTap: diphtheria/Tetanus/acellular pertussis, adult dose (lower than infant dose).encephalitis, as evidenced by studies conducted during the early
1950s (four cases per 1000 reported among vaccinated children
aged <6 months) [45,46]. The EU label for yellow fever vaccine also
contains a warning for vaccinating adults above 60 years for which
the decision to vaccinate should be made on a case-by-case basis
after weighting the risk of contracting the disease against the
potential of vaccine-associated neurotropic and viscerotropic dis-
ease, in subjects >60 years [47–49]. It is thus essential that public
health advisory bodies possess all available safety information in
order to make appropriate recommendations. This requires that
companies and other involved bodies (regulators, advisory groups,
public health authorities and the research community) collaborate
and exchange all available safety data on vaccines used worldwide.
This also requires that the regular submission of periodic safety
update report (PSUR) by the companies as well as safety data gath-
ered from the field by all stakeholders should be made publicly
accessible and that updated data on specific products regularly
be published.
Another issue surrounds legal consequences associated with
adverse events potentially related to vaccines usedoff-label. If a pro-
duct use is based on its label, regulators or the companymay be held
responsible for the adverse events that occur. Conversely, if a public
health authority recommends the use outside the label, the health
authoritycouldbeheld responsible for theadverseevents thatoccur.
A challenge is that potential adverse events are reported based
of their temporal association with the vaccine administration,
regardless of causality [50]. An assessment of an adverse event
report is necessary to determine if some causal relationship exists
or may exist between the vaccination and the adverse event and if
these points to a vaccine related (due to the inherent characteris-
tics of the vaccine or production problems) or programmatic issue,
or whether the relationship was merely coincidental. This assess-
ment requires a strong collaboration between all stakeholders. If
the assessment is that there is a causal relationship, then the man-
ufacturer and public health authorities should collaborate and give
due diligence to try to understand the potential biological mecha-
nisms resulting in the adverse event.
For example, pregnant women may be vulnerable to a number
of adverse events related to the pregnancy and it is difficult to dis-
tinguish whether the event was due to the vaccine or to an unre-
lated event that was temporally linked.13
The biggest challenge lies in reducing discrepancies between
authorised vaccine use and public health recommended use that
falls outside the current label but is based on sound evidence gener-
ated after the initial label. This discrepancy will not align until the
label is updated to reflect the new evidence. Reducing these discrep-
anciesdependson thewillingnessof the company to apply for a label
change and the regulators to approve the requested change.
Key barriers to changing a vaccine label include:
 The reluctance of the companies to apply for a label change to
extend the vaccine use to additional groups. This reluctance
may be driven by liability concerns (especially regarding preg-
nant women and their foetuses when vaccine use is not clearly
indicated) and/or the absence of a sufficient market, e.g. when
the proposed extension of use on the label concerns a very small
population group at risk and there is little economic incentive.
 The reluctance of the regulators to accept the label change after
assessment if the evidence is found insufficient to support the
label change. This may occur when data is derived from uncon-
trolled, non-randomized clinical trials, or from observational
studies (e.g. case control or cohort studies or surveillance).13 An adverse event is not necessarily causal related. Any event temporarily related
to a medical act is an adverse event. A medicinal product label has a lot of temporal,
not necessary causal related adverse events.
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most countries only the company may apply to amend the label
of a licensed product. Even when an independent body has pub-
lished evidence, the regulator cannot change the label without
the company’s application. However in some countries (e.g. in
the EU), regulatory bodies can impose on companies to change
the label (e.g. class label for the use of TIV in pregnant women).
 Regulatory authorities have the authority to require manufac-
turers to amend their label based on new information relating
to safety and efficacy. However a mechanism is required to
ensure that regulatory authorities are alerted and take action
in light of new information.
6. The way forward
The most effective way to reduce differences between the vac-
cine label and public health recommended use would be for com-
panies and regulators to collaborate on adapting the label as much
as possible to meet the public health and target population needs.
Label changes should be based on suitable evidence.
Vaccine clinical development is far from being finalised when it
first reaches the market. Post-licensure studies are needed and
should be agreed at the time of vaccine introduction. This concept
could be officially introduced in the regulatory approval process in
countries, and require that all involved parties (industry, regula-
tors, public health bodies) work together towards a well-defined
post-licensure programme, including how to share the respective
tasks, responsibilities and costs. This programme could cover epi-
demiological surveillance, studies of different specific population
and risk groups, alternative schedules, co-administration with
other vaccines, etc. The purpose of the post-marketing risk man-
agement plan (RMP) 14 is to generate additional data that are not
available at the time of granting the marketing authorisation
[6,51]. The RMP should cover a long time period and should be
revised if new evidence arises.
Regulators have a key role to play in requesting vaccine compa-
nies to collect or generate the missing evidence that would allow,
through regulatory procedures, to adapt the label to the public
health needs. Regulators are not always aware of the full impact
of the vaccine at the time of the adoption of the benefit/risk anal-
ysis. Additional data may be generated on specific population
groups (e.g. pregnant women, persons with underlying diseases)
but may also involve other dosage or schedule recommended by
NITAGs. Post-marketing data are also gathered by academic and
public health institutions and should be evaluated and incorpo-
rated as well, after assessment of their quality. Companies may
also be requested to collect and report post-marketing data on
inadvertent use of the vaccine, such as safety data on vaccine use
during pregnancy.
As stated by Chocarro et al. [1] there is need for increased and
more formal interactions between NRAs, NITAGs and immuniza-
tion programmes and for a clear framework establishing a formal
interaction and early interactions between these bodies before
market authorization. The NITAG should be encouraged to
approach the NRA when a potential for off-label use is identified
and then the NRA should set up the review process leading to a
request for the manufacturer to provide the necessary data.
NRA experts serving as ex-officio members on NITAGs and
NITAGs’ members or immunization managers serving on NRA
review panels are solutions which can be adopted by countries. If
there is a need to make recommendations that are not covered
by the license evidence, then there should be interactions between14 Risk Management Plan: The risk Management Plan is an EU obligation for the
Marketing Authorization Holders to further study both efficacy and safety of the
medicinal product once it has been granted a marketing authorization.the NITAG, the NRA and the license holder to encourage the license
holder to submit appropriate evidence, or to ensure that the justi-
fication for the off-label recommendation is communicated to the
recipients of the vaccine.
Another approach would be that the regulatory authority sets
up an independent review board to assess the label requested for
a new vaccine by a company, with the possibility to recommend
studying the vaccine in additional groups that were not requested
for the initial label. This is similar to the US Best Pharmaceuticals
for Children Act (BPCA), enacted in 2002, that requires that any
new drug that requests FDA approval without having a label for
use in children be presented to an oversight board composed of
pediatric experts to determine if there is a need for the drug in
children [52,53]. If this is the case the US FDA can require the
company to conduct relevant phase IV studies after the drug is
approved.
Regulatory processes are generally conservative and averse to
exposing patients or the public to unknown risks, but it can happen
that for some vaccinators, the unknown risks can appear to out-
weigh the known benefits, as has happened in some instances with
the use of influenza vaccines in pregnant women despite the WHO
recommendation that pregnant women were the highest priority
group for vaccination [54–56].
Another aspect to address is the difference in information avail-
able to regulators versus to public health groups. As the detailed
data submitted by the company for registration are not publicly
available, the rationale of the regulator’s decision to warn against
use of a vaccine in a certain group should be communicated when
justified by a negative benefit risk evaluation. This involves provid-
ing a summary of the detailed data and scientific discussion and
making them available to all stakeholders in a transparent way
(e.g. EMA European Public Assessment Report).
In addition, the use of ‘‘class effect”, as explained above, may be
accepted by regulators (on a case-by-case basis) to extend the label
to other groups, as illustrated by the generic wording for TIV in
pregnancy based on class label in the EU (see above) [20,21].
Since off-label recommendations will persist, it is important
that NRAs and public health authorities clearly and jointly commu-
nicate on the differences between the off-label recommendations
and the labels and why these are justified. This is important for
the credibility of each group and for the acceptance of the
recommendations.7. Conclusion
Discrepancies exist between the public health recommenda-
tions and the labelled use of some vaccines. Boundaries of off-
label use are not so firmly defined and vary between countries.
Also, differences in the legislation across countries and liability
aspects have an impact in these matters. An approach to decrease
discrepancies would be that regulators require vaccine companies
to provide evidence to adapt the label as much as possible to the
public health needs, during the whole life-cycle of a product. This
would require collecting and reporting post-marketing data by the
company and the NRA, communicating them to all stakeholders
and extrapolating existing evidence (when the data are adequate)
to other groups or to other brands of a vaccine (class effect). Where
companies request a label change based on new data, regulators
should conduct a benefit risk balance assessment based on all
available evidence, which should be made available to all stake-
holders. Good communication between regulatory and public
health authorities should be encouraged to harmonise vaccine
label with the local recommendations. Exchanges of information
and close collaboration between immunization programmes,
NITAGs, and NRAs are essential.
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